Skip to main content
. 2018 Jul 5;2:PO.17.00285. doi: 10.1200/PO.17.00285

Fig 3.

Fig 3.

The Translocation-Specific Sarcoma Sequencing assay (TranSS-Seq) detects circulating tumor DNA (ctDNA) in Ewing sarcoma (EWS) and alveolar rhabdomyosarcoma (aRMS). (A) DNA extracted from the EW8 cell line was serially diluted with normal DNA extracted from CEPH1347-2. Sequencing libraries were made in duplicate and sequenced with TranSS-Seq to detect the EWSR1/FLI translocation. Samples are plotted on the x-axis by the percentage of EW8 by experimental dilution and on the y-axis by the percentage of EW8 DNA detected by digital droplet polymerase chain reaction (ddPCR). The line drawn on the plot is a linear regression curve of the data (slope, 0.66). (B) Percentage of EW8 DNA was determined from the same samples as in panel A by TranSS-Seq and plotted on the y-axis (slope, 0.6). (C) The same samples as in panels A and B with percentage of EW8 DNA by TranSS-Seq on the x-axis and ddPCR on the y-axis (slope, 0.83). (D) Percentage of ctDNA levels in cell-free DNA samples from patients with Ewing sarcoma and aRMS (same samples as in Figure 1B) determined by TranSS-Seq. (E) Comparison of percentage of ctDNA detected in Ewing sarcoma and alveolar rhabdomyosarcoma samples determined by TranSS-Seq on the x-axis and ddPCR on the y-axis (slope, 1.63).